Clinical Trials Browser

Breast Neoplasms × gedatolisib × Clear all

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02684032 2022-07-27

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

Breast Neoplasms

NCT03698383 2021-02-18

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03243331 2021-01-07

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Phase 1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03400254 2020-04-28

GLACIER

Phase 1/2 Withdrawn

Breast Neoplasms

NCT02069158 2019-05-21

IOSI-NDU-001

Phase 1 Completed

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma